Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1470741
European Journal of Endocrinology, Vol 147, Issue 6, 741-745
Copyright © 2002 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lam, K.
Right arrow Articles by Leung, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lam, K.
Right arrow Articles by Leung, P.
Articles

High prevalence of RET proto-oncogene activation (RET/PTC) in papillary thyroid carcinomas

KY Lam, CY Lo, and PS Leung

Division of Pathology, School of Medicine, James Cook University, Townsville, Queensland, Australia.

OBJECTIVE: The activation of RET proto-oncogene, through different types of chromosomal translocation and inversion, is unique to papillary thyroid carcinomas (PTC) and its frequency is variable in different populations. The aim of this study was to investigate the frequency and types of PTC genetic rearrangements in papillary carcinoma in a population of Hong Kong Chinese. METHODS: The presence of RET/PTC1, RET/PTC2 and RET/PTC3 activation was analyzed by RT-PCR in twenty PTC from adult patients (age range 24-63 years), one PTC from a 12-year-old boy and anaplastic carcinomas in two adult patients. RESULTS: RET/PTC3 was the only activation of RET proto-oncogene identified in the samples. Seventeen PTC from adult patients (85%t) were positive for RET/PTC3. RET/PTC3 was also identified in PTC from the child and one of the two patients with anaplastic thyroid carcinoma. CONCLUSIONS: The prevalence of RET/PTC activation in PTC is high and RET/PTC3 is the only type of activation identified in Hong Kong Chinese and is an important genetic event underlying the development of PTC in the population.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
A. K. Y. Lam, C. Y. Lo, P. Leung, B. H. H. Lang, W. F. Chan, and J. M. Luk
Clinicopathological Roles of Alterations of Tumor Suppressor Gene p16 in Papillary Thyroid Carcinoma
Ann. Surg. Oncol., May 1, 2007; 14(5): 1772 - 1779.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J Di Cristofaro, V Vasko, V Savchenko, S Cherenko, A Larin, M D Ringel, M Saji, M Marcy, J F Henry, P Carayon, et al.
ret/PTC1 and ret/PTC3 in thyroid tumors from Chernobyl liquidators: comparison with sporadic tumors from Ukrainian and French patients
Endocr. Relat. Cancer, March 1, 2005; 12(1): 173 - 183.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Sadetzki, R. Calderon-Margalit, B. Modan, S. Srivastava, and R. M. Tuttle
Ret/PTC Activation in Benign and Malignant Thyroid Tumors Arising in a Population Exposed to Low-Dose External-Beam Irradiation in Childhood
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2281 - 2289.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 European Society of Endocrinology.